Pfizer-BioNTech and Moderna this week asked the Food and Drug Administration to authorize new bivalent COVID-19 booster vaccines designed to target both the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 lineages now dominating U.S. infections, setting up a regulatory decision that could reshape the fall vaccination campaign within weeks.

Pfizer and BioNTech submitted their application August 22 for a 30-microgram booster in people 12 and older. Moderna followed August 23 with an application for a 50-microgram dose of its BA.4/BA.5 bivalent candidate, mRNA-1273.222, for adults 18 and older, according to the company’s submission announcement.

The vaccine composition is changing with the virus

The strategy represents a significant transition from the first generation of COVID-19 vaccines. Current U.S. vaccines are based on the ancestral strain identified early in the pandemic. The proposed boosters retain that component but add messenger RNA encoding the spike protein shared by the BA.4 and BA.5 Omicron lineages.

FDA made that direction explicit on June 30, when it asked manufacturers to develop bivalent boosters with a BA.4/BA.5 component for fall and winter. The agency said the original composition should remain in primary vaccination for now while updated boosters add an Omicron component.

The recommendation followed a public June 28 meeting of FDA’s Vaccines and Related Biological Products Advisory Committee. Members voted in favor of including an Omicron component in future boosters after reviewing evidence on variant evolution, vaccine effectiveness and immune response.

That sequence resembles the strain-selection process used for influenza vaccines, but the science and regulatory framework for SARS-CoV-2 are still evolving. The virus has changed rapidly, and the dominant lineage at the time a vaccine is designed may not remain dominant throughout the season in which the vaccine is administered.

BA.5 provides the immediate rationale

As of August 24, CDC estimates BA.5 accounts for 88.7 percent of U.S. infections, with BA.4.6 at 7.5 percent and BA.4 at 3.6 percent. The agency’s August 26 surveillance report shows that Omicron lineages remain responsible for essentially all circulating virus nationwide.

BA.5’s dominance has increased pressure to deploy a vaccine better matched to current strains before colder weather and increased indoor activity. Existing vaccines continue to provide meaningful protection against severe illness, particularly after boosting, but neutralizing-antibody protection against infection has weakened as Omicron sublineages have accumulated mutations.

FDA’s bet is that a bivalent formulation can preserve the broader immune foundation created by the original-strain component while improving recognition of BA.4 and BA.5. Whether that translates into materially stronger protection against infection, severe disease or both will be followed closely once the vaccines enter widespread use.

Regulators are evaluating a mix of evidence

The accelerated timeline means FDA will not have large human efficacy trials of the exact BA.4/BA.5 formulations before a fall decision. Pfizer says its submission draws on clinical safety and immunogenicity data from an earlier Omicron-adapted bivalent vaccine targeting BA.1, together with preclinical and manufacturing data for the BA.4/BA.5 formulation. Moderna similarly says its application combines preclinical BA.4/BA.5 data with human clinical evidence from its BA.1 bivalent candidate.

That evidentiary approach has generated debate among vaccine specialists. Supporters argue that mRNA platform manufacturing is well understood, the basic vaccine backbone is unchanged and waiting for months of new human data could make variant-specific updates obsolete before they are deployed. Others want clearer evidence about the additional clinical benefit of the updated formulation and the durability of any improvement.

The FDA advisory committee’s June discussion provides much of the public framework for that tradeoff. Regulators are trying to move faster than the virus while maintaining a sufficiently strong safety and immunogenicity basis for authorization. The decision is especially consequential because the administration is preparing to make the updated shots the centerpiece of a national booster campaign.

Manufacturing and procurement are already in motion

The federal government has positioned supply before authorization. In June, Pfizer and BioNTech announced a U.S. agreement for 105 million doses through the fourth quarter, a purchase that could include Omicron-adapted vaccines if FDA authorizes them. The contract includes options for additional doses.

Pfizer says it has scaled production and is prepared to begin shipping the BA.4/BA.5 booster in September if authorized. The companies also completed an August 26 submission to the European Medicines Agency for the same BA.4/BA.5-adapted bivalent product, underscoring that regulators on both sides of the Atlantic are confronting similar timing questions.

Moderna likewise says it is ready to ship its updated booster in September pending FDA action. If both products are cleared, the U.S. campaign could begin with two age-specific authorizations: Pfizer-BioNTech for people 12 and older and Moderna for adults 18 and older, subject to the exact terms FDA chooses.

A regulatory decision could come quickly

The applications arrive only days before Labor Day and at a moment when federal health officials are trying to simplify COVID-19 vaccination into a more predictable seasonal strategy. But SARS-CoV-2 has not yet settled into a stable seasonal pattern, and booster recommendations still depend on age, risk, prior doses and the interval since the most recent vaccination.

If FDA authorizes the bivalent products, the Centers for Disease Control and Prevention will still need to issue clinical recommendations before a broad campaign begins. CDC’s Advisory Committee on Immunization Practices is expected to evaluate how the updated boosters should be used and for whom.

For now, the immediate fact is that both major U.S. mRNA vaccine manufacturers have completed the applications FDA requested. The next question is whether regulators judge the combination of prior clinical experience, Omicron-adapted human data, BA.4/BA.5 preclinical data and manufacturing evidence sufficient to move the country to an updated booster before fall transmission accelerates.